New drug duo takes on hard-to-treat breast cancer
NCT ID NCT07413601
First seen Feb 17, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tests whether adding the experimental drug QL1706 to standard chemotherapy helps people with advanced triple-negative breast cancer live longer without their disease getting worse. About 78 adults who have already tried one or two prior treatments will be randomly assigned to get either the drug combo or chemo alone. The goal is to see if the combination slows cancer growth better than chemo by itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 17 Panjiayuan Nan Li, Chaoyang District, Beijing
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.